Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.

Volltext-Artikel, E-Books und Literaturhinweise aus dem EBSCO Discovery Service

"Artikel & mehr" berücksichtigt nur einen Teil der für die Bibliothek der Frankfurt UAS verfügbaren Datenbanken. Zur Übersicht in DBIS

Ergebnis verändern

einschränken: Volltextzugriff; Academic (peer-reviewed) journals
erweitern: Auch Volltexte der Artikel durchsuchen; Verwandte Themen suchen

Publikationstyp

Thema

erschienen in

Verlag

Geographic terms

Sprache

Datenbank

Erscheinungsjahr

Von:

Bis:

Treffer 1 - 25 von 1236, Suchdauer: 1.2s

12 3 4 5 6 7 8 9 10 11 weiter »

1
Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials

von María-Victoria Mateos ; Suzanne Trudel ; Hang Quach ; et al.

Blood Advances, Vol 9, Iss 22, Pp 5708-5719 (2025)

Schlagworte: Specialties of internal medicine; RC581-951
- View full text via DOI
Merkliste

2
Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma Group

von Jiri Minarik ; Ludek Pour ; Vojtech Latal ; et al.

BMC Cancer, Vol 25, Iss 1, Pp 1-11 (2025)

Schlagworte: Multiple myeloma; Relapsed/refractory; Lenalidomide triplets; Risk groups; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- View full text via DOI
Merkliste

3
Final Results of a Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

von Barry Paul ; Jiri Minarik ; Francesca Cottini ; et al.

eJHaem, Vol 6, Iss 3, Pp n/a-n/a (2025)

Schlagworte: carfilzomib; daratumumab; dexamethasone; magrolimab; pomalidomide; relapsed/refractory multiple myeloma; Diseases of the blood and blood-forming organs; RC633-647.5
- View full text via DOI
Merkliste

4
Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies

von Paul G. Richardson ; Aurore Perrot ; Joseph Mikhael ; et al.

Blood Cancer Journal, Vol 14, Iss 1, Pp 1-11 (2024)

Schlagworte: Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- View full text via DOI
Merkliste

5
Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies

von Viera Sandecka ; Tereza Popkova ; Martin Stork ; et al.

Blood Cancer Journal, Vol 13, Iss 1, Pp 1-8 (2023)

Schlagworte: Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- View full text via DOI
Merkliste

6
Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis

von Paul G. Richardson ; Aurore Perrot ; Jesus San Miguel ; et al.

Haematologica, Vol 999, Iss 1 (2024)

Schlagworte: Diseases of the blood and blood-forming organs; RC633-647.5
- View full text via DOI
Merkliste

7
Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study

von Fredrik H. Schjesvold ; Heinz Ludwig ; Sossana Delimpasi ; et al.

Haematologica, Vol 999, Iss 1 (2024)

Schlagworte: Diseases of the blood and blood-forming organs; RC633-647.5
- View full text via DOI
Merkliste

8
Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma

von Cyrille Hulin ; Meral Beksac ; Hugh J. Goodman ; et al.

Blood Cancer Journal, Vol 11, Iss 10, Pp 1-4 (2021)

Schlagworte: Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- View full text via DOI
Merkliste

9
P1294: REAL-WORLD OUTCOMES OF 2149 NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS

von Tereza Popková ; Ludek Pour ; Ivan Spicka ; et al.

HemaSphere, Vol 7, p e0151603 (2023)

Schlagworte: Diseases of the blood and blood-forming organs; RC633-647.5
- View full text via DOI
Merkliste

10
P968: ALLOCATION AND VALIDATION OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM IN THE ICARIA-MM AND IKEMA STUDIES

von Aurore Perrot ; Paul Richardson ; Joseph Mikhael ; et al.

HemaSphere, Vol 7, p e3398301 (2023)

Schlagworte: Diseases of the blood and blood-forming organs; RC633-647.5
- View full text via DOI
Merkliste

11
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study

von Luděk Pour ; Monika Szarejko ; Jelena Bila ; et al.

Haematologica, Vol 109, Iss 3 (2023)

Schlagworte: Diseases of the blood and blood-forming organs; RC633-647.5
- View full text via DOI
Merkliste

12
P944: REAL-WORLD PATIENT CHARACTERISTICS AND SURVIVAL OUTCOMES OF LENALIDOMIDE REFRACTORY VS. LENALIDOMIDE EXPOSED RRMM PATIENTS IN THE HONEUR FEDERATED DATA NETWORK

von Ivan Spicka ; Ido Lapidot ; Maximilian Merz ; et al.

HemaSphere, Vol 7, p e258126d (2023)

Schlagworte: Diseases of the blood and blood-forming organs; RC633-647.5
- View full text via DOI
Merkliste

13
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab

von Joseph Mikhael ; Karim Belhadj-Merzoug ; Cyrille Hulin ; et al.

Blood Cancer Journal, Vol 11, Iss 5, Pp 1-5 (2021)

Schlagworte: Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- View full text via DOI
Merkliste

14
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice

von Jiri Minarik ; Tomas Pika ; Jakub Radocha ; et al.

BMC Cancer, Vol 21, Iss 1, Pp 1-13 (2021)

Schlagworte: Multiple myeloma; Ixazomib; Lenalidomide; Dexamethasone; Clinical trial; Patient registry; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- View full text via DOI
Merkliste

15
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

von Katja Weisel ; Andrew Spencer ; Suzanne Lentzsch ; et al.

Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-11 (2020)

Schlagworte: Clinical trials; Multiple myeloma; Myeloma therapy; Diseases of the blood and blood-forming organs; RC633-647.5; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- View full text via DOI
Merkliste

16
De-escalated Teclistamab dosing in relapsed/refractory multiple myeloma: Czech myeloma group real-world evidence analysis

von Stork, Martin ; Radocha, Jakub ; Mihalyova, Jana ; et al.

Annals of Hematology. :1-7
- Volltextverfügbarkeit prüfen (via ReDI)
Merkliste

17
Randomized, placebo‐controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib

von Paul G. Richardson ; Arnon Nagler ; Dina Ben‐Yehuda ; et al.

eJHaem, Vol 1, Iss 1, Pp 94-102 (2020)

Schlagworte: Akt inhibition; bortezomib; multiple myeloma; perifosine; proteasome inhibition; Diseases of the blood and blood-forming organs; RC633-647.5
- View full text via DOI
Merkliste

18
Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA

von Tom Martin ; Paul G Richardson ; Thierry Facon ; et al.

Haematologica, Vol 107, Iss 10 (2022)

Schlagworte: Diseases of the blood and blood-forming organs; RC633-647.5
- View full text via DOI
Merkliste

19
Treatment Patterns and Outcomes in Over 2200 Newly Diagnosed Multiple Myeloma Patients: Supporting Bortezomib-Lenalidomide-Dexamethasone as a Preferred Regimen in the Absence of Anti-CD38 Antibodies

von Jungova, Alexandra ; Stork, Martin ; Spicka, Ivan ; et al.

In Clinical Lymphoma, Myeloma and Leukemia April 2026 26(4):e470-e482
- View full text via DOI
Merkliste

20
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma

von Saad Z. Usmani ; Hareth Nahi ; Wojciech Legiec ; et al.

Haematologica, Vol 107, Iss 10 (2022)

Schlagworte: Diseases of the blood and blood-forming organs; RC633-647.5
- View full text via DOI
Merkliste

21
ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: IKEMA SUBGROUP ANALYSIS

von Mehmut TURGUT ; Roman HAJEK ; Tomas JELÍNEK ; et al.

Hematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S18- (2021)

Schlagworte: Diseases of the blood and blood-forming organs; RC633-647.5
- View full text via DOI
Merkliste

22
Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected 'real-world' population

von Jiri Minarik ; Ludek Pour ; Vladimir Maisnar ; et al.

Biomedical Papers, Vol 163, Iss 3, Pp 279-283 (2019)

Schlagworte: multiple myeloma; relapsed and refractory; daratumumab; progression free survival; overall survival; Medicine
- View full text via DOI
Merkliste

23
BRIDGE (OP-107): A Phase 2 Pharmacokinetic Study of Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Impaired Renal Function

von Pour, Ludek ; Delimpasi, Sosana ; Legiec, Wojciech ; et al.

In Clinical Lymphoma, Myeloma and Leukemia April 2026
- View full text via DOI
Merkliste

24
Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma: dynamics of MRD negativity in the IMROZ study

von Orlowski, Robert Z. ; Dimopoulos, Meletios A. ; Leleu, Xavier ; et al.

In Blood December 2025
- Volltextverfügbarkeit prüfen (via ReDI)
Merkliste

25
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial

von Chandra, Abhinav ; Bryant, Adam ; Oriol, Albert ; et al.

In The Lancet Haematology August 2025 12(8):e599-e610
- View full text via DOI
Merkliste

12 3 4 5 6 7 8 9 10 11 weiter »

Sie haben nicht gefunden, wonach Sie gesucht haben? Diese Services können Ihnen weiterhelfen.
Hilfe & Kontakt ǀ Fernleihe | Hilfe zur Fernleihe ǀ Literaturvorschlag| Literaturvorschlag